News

Fda approves Zevaskyn for rare, genetic skin disorder
The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with ...
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...
Medscape19h
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...
The Pharma Letter2h
FDA approves Abeona’s Zevaskyn
The US Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also ...
Healio23h
FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa
The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...
US FDA approves first cell-based gene therapy for rare genetic skin disorder
The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday. The ...
Health and Me on MSN11h
FDA Greenlights Zevaskyn for Rare Genetic Skin Condition
With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...
BioPharma Dive22h
Abeona cell therapy approved by FDA for rare skin condition
Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy
The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Zevaskyn ...
MedPage Today on MSN17h
FDA OKs New Gene Therapy for Debilitating Skin Condition
Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...
pharmaphorum2h
Abeona prices rare cell disorder gene therapy at $3.1m
Abeona Therapeutics' Zevaskyn, a cell therapy based on engineered keratinocytes harvested from patients, has been approved in ...